Overview
Spirair develops minimally invasive ENT medical devices. The flagship SeptAlign system uses a bioabsorbable implant to mechanically straighten minor nasal septal deviations through an in-office procedure that can be done with local anesthesia; the implant dissolves in about six months after the cartilage maintains its new shape. In 2025, Spirair added TurbAlign, a bioabsorbable implant designed to separate the middle turbinate from the nasal wall to aid healing after sinus surgery. The devices are sold to ENT doctors and designed to preserve tissue and shorten recovery compared with traditional septoplasty, aiming to improve nasal airflow and expand access to less invasive nasal correction.
Work here?Claim your company
Simplify's take
What believers are saying
- Spirair secured two FDA clearances within seven months, broadening its ENT device portfolio.
- The company updated news through August 2026, indicating active commercial and regulatory momentum.
- Local-anesthesia office procedures attract ENTs seeking faster throughput than operating-room septoplasty.
What critics are saying
- Cigna's 2026 policy excludes absorbable nasal implants, crushing reimbursement for Spirair sales.
- Septoplasty remains broadly covered in 2026, keeping cheap surgical incumbents entrenched.
- Spirair filed a 2025 exempt offering for $23.6 million, signaling continuing capital dependence.
What makes Spirair unique
- SeptAlign won FDA clearance on January 16, 2026 for nasal septal deviation.
- TurbAlign won FDA clearance on July 11, 2025 for post-sinus-surgery healing support.
- Stanford Biodesign founders Brandon McCutcheon and James Kintzing built a surgeon-led ENT platform.
Help us improve and share your feedback! Did you find this helpful?